News

The average one-year price target for Revelation Biosciences (NasdaqCM:REVB) has been revised to 40.04 / share. This is an increase of 242.79% from the prior estimate of 11.68 dated January 16, 2024.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 39.64 to a high of 41.21 / share. The average price target represents an increase of 1,329.82% from the latest reported closing price of 2.80 / share.

What is the Fund Sentiment?

There are 13 funds or institutions reporting positions in Revelation Biosciences. This is a decrease of 1 owner(s) or 7.14% in the last quarter. Average portfolio weight of all funds dedicated to REVB is 0.01%, a decrease of 0.91%. Total shares owned by institutions increased in the last three months by 1.67% to 976K shares.

What are Other Shareholders Doing?

Walleye Capital holds 413K shares representing 122.14% ownership of the company. In it's prior filing, the firm reported owning 391K shares, representing an increase of 5.31%. The firm decreased its portfolio allocation in REVB by 35.64% over the last quarter.

Sabby Management holds 403K shares representing 119.17% ownership of the company. No change in the last quarter.

Axa holds 56K shares representing 16.54% ownership of the company. No change in the last quarter.

Geode Capital Management holds 36K shares representing 10.55% ownership of the company. No change in the last quarter.

FSMAX - Fidelity Extended Market Index Fund holds 36K shares representing 10.55% ownership of the company.

Revelation Biosciences Background Information
(This description is provided by the company.)

Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.